‘How drunk do you feel?’: Ozempic, Wegovy may help reduce alcohol use

A pilot study by the Fralin Biomedical Research Institute indicates that GLP-1 agonists, including drugs like Ozempic and Wegovy, significantly slow alcohol absorption and reduce subjective feelings of intoxication by delaying gastric emptying. This finding suggests a potential new therapeutic application for these pharmaceuticals in reducing alcohol use, distinct from existing treatments, and could expand their market beyond diabetes and weight management, warranting further large-scale clinical trials.

Analysis

A pilot study from the Fralin Biomedical Research Institute, published in Scientific Reports, indicates that GLP-1 agonists like semaglutide, tirzepatide, and liraglutide significantly reduce subjective feelings of intoxication and slow alcohol absorption. This effect is attributed to the drugs' mechanism of delaying gastric emptying, which results in a slower increase in blood alcohol concentration. This represents a distinct pharmacological approach compared to existing alcohol reduction medications such as naltrexone and acamprosate, which act on the central nervous system.

The findings suggest a potential new therapeutic application for GLP-1 agonists, expanding their market beyond current indications for diabetes and weight management. With over half of U.S. adults consuming alcohol and one in ten having alcohol use disorder, this could address a significant public health need, as highlighted by the U.S. Surgeon General's advisory on alcohol's link to cancer. The positive sentiment around NVO (0.8) reflects the potential for market expansion for key players in the GLP-1 space.

While this was a pilot study involving 20 participants, the researchers noted clear differences between the GLP-1 and control groups. These early data provide a strong foundation for larger, more rigorous clinical trials to definitively assess the efficacy of GLP-1 drugs in reducing alcohol use. The initial idea was partly inspired by social media reports on Reddit, indicating a broader public interest in this potential benefit.

Key Decisions for Investors

• Investors should monitor ongoing clinical trials for GLP-1 agonists, particularly those from key manufacturers like Novo Nordisk (NVO), for further validation of their efficacy in reducing alcohol use.
• The potential for market expansion into alcohol use disorder treatment could significantly increase the total addressable market for GLP-1 drugs, warranting an assessment of long-term growth projections for companies in this sector.
• While promising, this remains early-stage research, and investment decisions should account for the regulatory hurdles and time required for new indications to be approved and commercialized.